Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA blood products cmte. should include plasma industry reps, ABRA tells Rep. Shays.

This article was originally published in The Gray Sheet

Executive Summary

BLOOD PLASMA INDUSTRY REPRESENTATION ON ADVISORY COMMITTEE should be allowed by FDA, American Blood Resources Association President James Reilly told a Nov. 2 hearing on blood safety before the House Government Reform/Human Resources Subcommittee. "All parties affected by the regulation of blood and plasma-based therapies -- including the fractionators -- should be represented on" FDA's Blood Products Advisory Committee, the plasma industry association president said.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT005008

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel